Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Acute Myeloid Leukemias · Breast Cancer

Syndax Pharmaceuticals

Syndax Pharmaceuticals clinical programs — 47 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
730 3rd Ave, Floor 9, New York, NY 10017, US HQ
325 Employees
NMPA registrant Type
Company details
Status
Public
HQ
730 3rd Ave, Floor 9, New York, NY 10017, US
Employees
325
Programs
47
Drugs
29
Patents
6
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Syndax Pharmaceuticals projects

47 ClinicalTrials.gov programs sponsored by Syndax Pharmaceuticals.

Syndax Pharmaceuticals has 47 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

47 programs

Clinical programs

  1. Revumenib

    Syndax Pharmaceuticals

    Acute Myeloid Leukemias

    phase 3 small molecule active

    1 trial

  2. SNDX-5613-0710

    Syndax Pharmaceuticals

    Newly Diagnosed AML with an NPM1 mutation

    phase 3 small molecule active

    1 trial

  3. AXATILIMAB

    Syndax Pharmaceuticals

    Chronic graft versus host disease (cGVHD)

    phase 2 small molecule active

    1 trial

  4. AXATILIMAB, Placebo

    Syndax Pharmaceuticals

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  5. Atezolizumab

    Syndax Pharmaceuticals

    Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  6. Axatilimab

    Syndax Pharmaceuticals

    Chronic Graft-versus-host-disease

    phase 2 small molecule active

    2 trials

  7. Axatilimab

    Syndax Pharmaceuticals

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  8. Azacitidine

    Syndax Pharmaceuticals

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  9. Durvalumab

    Syndax Pharmaceuticals

    Unresectable Intrahepatic Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  10. Entinostat

    Syndax Pharmaceuticals

    Metastatic Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  11. Entinostat

    Syndax Pharmaceuticals

    ER+ Breast Cancer

    phase 2 small molecule completed

    1 trial

  12. Entinostat

    Syndax Pharmaceuticals

    Non Small Cell Lung Cancer

    phase 2 small molecule terminated

    2 trials

  13. Entinostat

    Syndax Pharmaceuticals

    Hodgkin's Lymphoma

    phase 2 small molecule terminated

    1 trial

  14. Entinostat

    Syndax Pharmaceuticals

    Renal Cell Carcinoma

    phase 2 small molecule active

    2 trials

  15. Entinostat

    Syndax Pharmaceuticals

    Lymphoma

    phase 2 small molecule active

    1 trial

  16. Entinostat

    Syndax Pharmaceuticals

    Melanoma

    phase 2 small molecule completed

    1 trial

  17. Entinostat

    Syndax Pharmaceuticals

    Non-Small-Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  18. Fulvestrant

    Syndax Pharmaceuticals

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  19. Pembrolizumab

    Syndax Pharmaceuticals

    Metastatic Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  20. Pembrolizumab

    Syndax Pharmaceuticals

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  21. Revumenib

    Syndax Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule active

    2 trials

  22. Revumenib

    Syndax Pharmaceuticals

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  23. Revumenib

    Syndax Pharmaceuticals

    Leukemia

    phase 2 small molecule active

    1 trial

  24. Revumenib

    Syndax Pharmaceuticals

    Relapsed Adult AML

    phase 2 small molecule active

    1 trial

  25. SNDX-5613

    Syndax Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  26. SNDX-5613-0700

    Syndax Pharmaceuticals

    Relapsed or Refractory Acute Leukemias

    phase 2 small molecule active

    1 trial

  27. SNDX-6352

    Syndax Pharmaceuticals

    Coronavirus

    phase 2 small molecule terminated

    1 trial

  28. Venetoclax

    Syndax Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  29. entinostat

    Syndax Pharmaceuticals

    Epithelial Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  30. entinostat

    Syndax Pharmaceuticals

    Estrogen Receptor-negative Breast Cancer

    phase 2 small molecule terminated

    1 trial

  31. entinostat

    Syndax Pharmaceuticals

    Breast Cancer

    phase 2 small molecule completed

    4 trials

  32. Axatilimab

    Syndax Pharmaceuticals

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  33. Entinostat

    Syndax Pharmaceuticals

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  34. Entinostat

    Syndax Pharmaceuticals

    Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial

  35. Entinostat

    Syndax Pharmaceuticals

    Volunteers

    phase 1 small molecule completed

    2 trials

  36. Entinostat

    Syndax Pharmaceuticals

    Neoplasms

    phase 1 small molecule completed

    2 trials

  37. Entinostat

    Syndax Pharmaceuticals

    Fallopian Tube Cancer

    phase 1 small molecule terminated

    1 trial

  38. Entinostat

    Syndax Pharmaceuticals

    Pancreas Cancer

    phase 1 small molecule terminated

    1 trial

  39. Entinostat

    Syndax Pharmaceuticals

    Drug Interaction

    phase 1 small molecule completed

    1 trial

  40. Revumenib

    Syndax Pharmaceuticals

    Acute Leukemia

    phase 1 small molecule completed

    1 trial

  41. Revumenib

    Syndax Pharmaceuticals

    Blinatumomab

    phase 1 small molecule active

    1 trial

  42. Revumenib

    Syndax Pharmaceuticals

    Refractory Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  43. Revumenib

    Syndax Pharmaceuticals

    Relapsed/Refractory Leukemias

    phase 1 small molecule completed

    1 trial

  44. SNDX-275

    Syndax Pharmaceuticals

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  45. SNDX-5613

    Syndax Pharmaceuticals

    Acute Myeloid Leukemias

    phase 1 small molecule active

    1 trial

  46. SNDX-5613-0708

    Syndax Pharmaceuticals

    Acute Myeloid Leukemias

    phase 1 other active

    1 trial

  47. entinostat

    Syndax Pharmaceuticals

    Lung Cancer

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Syndax Pharmaceuticals have?

47 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.